Xencor Inc
Xencor Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on engineered antibody therapeutics. The company develops XmAb-based drug candidates and antibody engineering technologies for cancer and autoimmune diseases, and it also licenses its platforms and candidates to collaborators.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueInternally discovered XmAb antibody candidates advanced through preclinical and clinical development.
Licenses to use Xencor's XmAb and Xtend platforms in partner programs.
Milestone payments earned when partners achieve development or regulatory events.
Ongoing royalty income from marketed products developed using Xencor technology.
Products
Reported · share of revenue- Royalty63.9 %
- Milestone36.1 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Xencor's direct customers are pharmaceutical and biotechnology partners that license its antibody engineering technologies or collaborate on drug candidates. The company also serves clinical and commercial end markets indirectly through its own pipeline and through partner-developed medicines that use XmAb technologies.
License Xencor's antibody engineering platforms and pay upfront, milestone, and royalty consideration.
Co-develop early-stage antibody programs and use Xencor's technology to accelerate discovery and clinical work.
Take over selected Xencor-originated candidates for later-stage development and potential commercialization.
The ultimate end market for Xencor's internal pipeline and partner programs, especially in unmet-need settings.
Strategy
Xencor's strategy is to use its XmAb protein engineering platform to create differentiated antibody therapeutics and then decide program-by-program whether to advance, partner, or discontinue assets. It seeks to retain economic upside through royalties, milestones, and commercial rights while using collaborators' development and commercialization capabilities where appropriate.
Clinical data determine which candidates can move toward later-stage development and potential commercialization.
Collaborations provide non-dilutive funding and external development capacity while preserving upside.
A broader technology base can generate more candidates, more partner programs, and more royalty-bearing products.
Geography
Xencor is headquartered in Pasadena, California and operates as a U.S.-based research and development company. Its business is global in scope because clinical trials, licensing, manufacturing, and commercialization activities can involve partners and regulators in the United States, Europe, and other foreign markets.
Risks
Xencor depends on successful clinical development, regulatory approval, and partner execution, all of which are uncertain in biopharmaceutical development. Its revenue is concentrated in collaboration, milestone, and royalty arrangements, so timing of partner events and the performance of marketed partner products can materially affect results.
- Capital requirements and dilutionImpact: HighLikelihood: High
Clinical-stage biopharma companies often need external financing before product sales are available.
Exposure: Pipeline funding and operating flexibility
- Clinical development failureImpact: HighLikelihood: Medium
Drug candidates may not show sufficient safety or efficacy to advance, which can end a program after significant R&D spend.
Exposure: Internal pipeline and co-development programs
- Regulatory approval riskImpact: HighLikelihood: Medium
Even promising candidates require FDA and foreign approvals before trials or commercialization can proceed.
Exposure: Global clinical and commercialization plans
- Partner concentration and execution riskImpact: HighLikelihood: Medium
Milestones and royalties depend on third-party partners advancing programs and selling products successfully.
Exposure - Intellectual property protectionImpact: MediumLikelihood: Low
The value of XmAb technologies depends on patent and license protection against imitation or disputes.
Exposure: Platform technologies and licensed candidates
Accounting
Judgemental itemsUpfront fees, milestones, and royalties must be allocated and recognized based on performance obligations and variable consideration.
Impact: Can materially shift revenue between periods
Royalties from marketed partner products depend on sales reports and may be recognized as non-cash revenue.
Impact: Creates recurring but partner-dependent revenue
Clinical and manufacturing services are often billed after work is performed, requiring estimates at period-end.
Impact: Affects operating expense timing
Investment gains, losses, and impairments flow through other income (expense), net.
Impact: Can add volatility outside core operations
Similar listed companies
Publicly listed companies with a comparable business focus.
Last updated: 24/09/2026